Selected publications

1. Poh AR, Love CG, Masson F, Preaudet A, Tsui C, Whitehead L, Monard S, Khakham Y, Burstroem L, Lessene G, Sieber O, Lowell C, Putoczki TL, O'Donoghue RJ, Ernst M. Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell. 2017 10;31(4): 563-575. PMID: 28399411
2. Lessene, G. Close encounter of the covalent kind: Inhibiting MCL1's proapoptotic activity with covalent inhibitors. Cell Death Discov. 2017. 23;3:16094. PMID: 28179993
3. Nhu D,  Lessene G, Huang DCS, Burns CJ. Small molecules targeting Mcl-1: The search for a silver bullet in cancer therapy. MedChemComm. 2016. 7(5), 778-787. doi: 10.1039/c5md00582e
4. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong J-N, Moujalled DM, Bruno A, Csekei M, Paczal Aa, Szabo ZB, Sipos S, Radics G,  Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard A-M, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LCA, Aubrey BJ, Brennan MS, Herold MJ, Chang C de, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland Fc, Hickman JA, Roberts AW, Huang DCS, Wei AH, Strasser A, Lessene G, Geneste O. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016. 538(7626), 477-482. PMID: 27760111
5. Jacobsen AV, Lowes KN, Tanzer MC, Lucet IS, Hildebrand JM, Petrie EJ, van Delft MF, Liu Z, Conos SA, Zhang JG, Huang DC, Silke J, Lessene G, Murphy JM. HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell Death Dis. 2016. 7, e2051. PMID: 26775703
6. Roy MJ, Vom A, Czabotar PE, Lessene G. Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway. Br J Pharmacol. 2014 Sep 30;171:1973-87. PMID: 24117105.
7. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63. PMID: 24355989.
8. Brady RM, Vom A, Roy MJ, Toovey N, Smith BJ, Moss RM, Hatzis E, Huang DC, Parisot JP, Yang H, Street IP, Colman PM, Czabotar PE, Baell JB, Lessene G. De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-XL: Synthesis, Structural and Biochemical Characterization. J Med Chem. 2014 Feb 27;57(4):1323-43. PMID: 24456288.
9. Sleebs BE, Kersten WJ, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss RM, Parisot JP, Yang H, Czabotar PE, Fairlie WD, Lee EF, Adams JM, Chen L, van Delft MF, Lowes KN, Wei A, Huang DC, Colman PM, Street IP, Baell JB, Watson K, Lessene G. Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-XL. Journal of Medicinal Chemistry. 2013 Jun 26;56(13):5514-40. PMID: 23767404.
10. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, Colman PM, Deshayes K, Fairbrother WJ, Flygare JA, Gibbons P, Kersten WJA, Kulasegaram S, Moss RM, Parisot JP, Smith BJ, Street IP, Yang H, Huang DCS, Watson KG. Structure-guided design of a selective BCL-XL inhibitor. Nature Chemical Biology. 2013;9(6):390-7.

More publications